ESR1 and breast cancer: The CDK4/6-targeted inhibitor treatment of advanced hormone-resistant and metastatic ER+ breast cancer has shown significant clinical benefit when combined with aromatase inhibitors (AIs) or selective estrogen receptor degraders (SERDs) [244].